Clinical trials: Thoracic Diseases
Non Small Cell Lung Cancer
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
The purpose of this study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa), in combination with pembrolizumab in patients with previously treated NSCLC.
- Trial name
- Acclaim-2 (NCT05062980)
- Testing
- quaratusugene ozeplasmid, pembrolizumab, docetaxel
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Genprex, Inc.
Lung Cancer, Lung Metastases
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using…
- Trial name
- VISUALIZE-2 (NCT07499674)
- Testing
- Abenacianine, Near Infrared (NIR) Imaging
- Where
- 9 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- Vergent Bioscience, Inc.
Lung Diseases, Lung Neoplasms
Observational Bronchoscopy Video Data Collection Study With Adult Patients
The primary aim is to develop a software algorithm that has the capacity to detect the normal 18 anatomical structures of the lung by using the position of the scope during the bronchoscopy procedure and using existing…
- Conditions
- Lung Diseases, Lung Neoplasms, Lung Cancer, Lung Transplantation
- Trial name
- NCT06465797
- Testing
- Bronchoscopy
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Ambu A/S
Lung Cancer, Cancer
Bintrafusp Alfa Program Rollover Study
This study is designed to provide continuous access to treatment with bintrafusp alfa for eligible participants from ongoing bintrafusp alfa parent studies (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706…
- Trial name
- NCT05061823
- Testing
- Bintrafusp alfa
- Where
- 21 sites in United States, Belgium and 10 more
- Volunteers
- 22 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non Small Cell Lung Cancer
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
This is a multi-center Phase 1 b study designed to expand the patient safety using 99mTc-EC-DG with SPECT/CT imaging and to expand the patient radiation dosimetry and pharmacokinetic database using 99mTc-EC-DG in patients who…
- Trial name
- NCT00864110
- Testing
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Cell>Point LLC
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Heart Disease, Stable Angina Pectoris
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
The objective of this study is a comparative evaluation of BuMA stent and of EXCEL stent in terms of the extent of neointima formation at 3 months after implantation using OCT.
- Conditions
- Coronary Heart Disease, Stable Angina Pectoris, Unstable Angina Pectoris, Silent Myocardial Ischemia
- Trial name
- NCT01752582
- Testing
- BuMA stent, EXCEL stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Non-Small Cell Lung Cancer
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.
- Trial name
- NCT05023746
- Testing
- Genetron lung cancer panel
- Where
- 4 sites in China
- Volunteers
- 1,052 people
- Sponsor
- Genetron Health
Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Pilot Phase II Study The primary objective for this study is: To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before…
- Conditions
- Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
- Trial name
- K5-101 (NCT00988936)
- Testing
- [F-18]RGD-K5
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Siemens Molecular Imaging
Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC
Expanded Access of Sotorasib
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer…
- Conditions
- Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
- Trial name
- NCT04667234
- Testing
- AMG 510
- Where
- 55 sites in United States, Argentina and 4 more
- Sponsor
- Amgen
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
- Trial name
- DeLLphi-312 (NCT07005128)
- Testing
- Tarlatamab, Durvalumab, Carboplatin
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Blunt Thoracic Aortic Injury
Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury
The purpose of this study is to determine if the Valiant stent graft is safe and effective in treating patients who have a blunt thoracic aortic injury (BTAI).
- Trial name
- RESCUE (NCT01092767)
- Testing
- Valiant Thoracic Stent Graft with the Captivia Delivery System
- Where
- 25 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Medtronic Cardiovascular
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Lung Cancer
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT01207011
- Testing
- Amrubicin hydrocloride, Docetaxel
- Where
- Japan
- Volunteers
- 202 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2)…
- Trial name
- NCT04380636
- Testing
- Pembrolizumab, Olaparib, Etoposide
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
Cancer
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Heat shock protein 90 (Hsp90) is a chemical in the body that is involve in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01892046
- Testing
- SNX-5422
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Esanex Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.